Pregled bibliografske jedinice broj: 247804
CASE OF CONCURRENT EPIDERMOLYSIS BULLOSA ACQUISITA AND ANTI¬ ; p200 PEMPHIGOID -HOW TO TREAT IT?
CASE OF CONCURRENT EPIDERMOLYSIS BULLOSA ACQUISITA AND ANTI¬ ; p200 PEMPHIGOID -HOW TO TREAT IT? // 3. Kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem
Split, Hrvatska, 2006. str. 79-80 (predavanje, nije recenziran, sažetak, stručni)
CROSBI ID: 247804 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
CASE OF CONCURRENT EPIDERMOLYSIS BULLOSA ACQUISITA AND ANTI¬ ; p200 PEMPHIGOID -HOW TO TREAT IT?
Autori
Paštar, Zrinjka ; Radoš, Jaka ; Lipozenčić, Jasna ; Dobrić, Ivan ; Marinović, Branka ; Ishii, Norito ; Hashimoto Takashi
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
3. Kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem
/ - , 2006, 79-80
Skup
3. Kongres hrvatskih dermatovenerologa s međunarodnim sudjelovanjem
Mjesto i datum
Split, Hrvatska, 18.05.2006. - 21.05.2006
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Nije recenziran
Ključne riječi
Epidermolysis abullosa acquisita anti-p200 pemphogoid treatment
Sažetak
We describe a 65-year-old man with a six year history of clinical, histological and immunological features of mixture of epidermolysis bullosa acquisita and anti-p200 pem¬ ; phigoid. Indirect immunofluorescence of 1M NaCl split human skin detected IgG anti¬ ; bodies reactive with dermal side. By immunoblotting of human dermal extracts, the patient sera reacted with both the 290 kDa type VII collagen and the p200. Previous treatment with corticosteroids in combination with dapsone, cyclosporine, or mycophenolate mophetil, resulted in moderate response but in numerous side-effects. Therefore, high-dose intravenous immunoglobulin therapy using commercially available preparation was employed. The therapy was well tolerated without side-effects by our patient. The result was promising. To date, one therapy course has been employed due to financial restrictions. We believe that repeated courses of high-dose intravenous immunoglobulins would reduce atrophic scarring and maintain the motility of palms and soles, as the symptom of the disease undisputedly leads to dermatogenic contractures and therefore is disabling the patient through life.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
0108166
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Jasna Lipozenčić
(autor)
Zrinjka Paštar
(autor)
Branka Marinović
(autor)
Ivan Dobrić
(autor)